View Older Stories View More Recent Stories
-
RedHill Biopharma Reports Results for the First Quarter of 2015
-
Lipocine Announces Closing of $34.8 Million Common Stock Offering
-
Lipocine Prices $30.2 Million Public Offering of Common Stock
-
Lipocine Prices $30.2 Million Public Offering of Common Stock
-
Hannon Armstrong Sustainable Infrastructure Capital, Inc. Announces the Pricing of its Public Offering of Common Stock
-
Roth Capital Starts Enerpulse Technologies (ENPT) at Buy
-
ROTH Capital Partners Expands Healthcare Practice with Addition of Michael Higgins as a Senior Research Analyst – Specialty Pharmaceuticals/Biotechnology
-
Roth Capital Downgrades Celladon Corp (CLDN) to Neutral
-
Cellceutix Selects Independent Directors and Committee Members
-
Roth Capital Starts RAVE Restaurant (RAVE) at Buy
-
Roth Capital Boosts PT on Green Plains (GPRE) to $40; Notes Improving Market Conditions, MLP Outlook
-
Lipocine (LPCN) Prices 4.65M Common at $6.50/Sahre
-
Lipocine Prices $30.2 Million Public Offering of Common Stock
-
Lipocine Prices $30.2 Million Public Offering of Common Stock
-
Roth Capital Starts Mast Therapeutics (MSTX) at Buy
-
Speed Commerce Announces Closing of Registered Direct Offering
-
Speed Commerce Announces Closing of Registered Direct Offering
-
Roth Capital Maintains TG Therapeutics (TGTX) at 'Buy' Following IRAK4 Inhibitor Compounds Presentation
-
Roth Affirms Aduro Biotech (ADRO) at 'Buy'; Novartis' (NVS) Data Validates Mesothelin CAR-T
-
Biodel (BIOD) Closes 37.5M Common Stock Offering
-
Roth Capital Remains Positive on Peregrine Pharma (PPHM) Following Bavituximab Presentation
-
Roth Capital Starts SolarEdge Technologies (SEDG) at Buy
-
Pre-Open Stock Movers 4/20: (HQCL) (ADRO) (HAS) Higher; (AMPE) (FARO) (RCL) Lower (more...)
-
UPDATE: Roth Capital Starts ADURO BIOTECH (ADRO) at Buy, PT $74
-
Roth Capital Upgrades CECO Environmental (CECE) to Buy; Management, Growth Opportunities to Drive 2015
-
Roth Capital Starts Crossroads Systems (CRDS) at Buy
-
ROTH China Solar Tour to be Held in Conjunction with SNEC Power Expo in Shanghai April 28-30
-
Speed Commerce (SPDC) Enters 13.04M Common Registered Direct Offering at $0.56/Share
-
Speed Commerce Announces Registered Direct Offering
-
Speed Commerce Announces Registered Direct Offering
-
LiquidSpace Introduces New App for iPhone Bringing Workspace Freedom to the Mobile Workforce
-
Unusual 11 Mid-Day Movers 4/15: (MCP) (VGGL) (VTG) Higher; (PAL) (DSKX) (ALU) Lower
-
Ballard Power (BLDP) Gets 'Nice' Win with Chinese HD7 Module Order; Roth Capital Comments
-
Biodel (BIOD) Prices 32.6M Common Share Offering at $0.92/Share
-
Biodel Announces Pricing of Public Offering of Common Stock
-
Roth Capital Starts Galmed Pharmaceuticals (GLMD) at Buy, PT $20
-
Roth Capital Starts Eco-Stim Energy (ESES) at Buy
-
LightBeam Electric (LEC) Files $100M IPO
-
Over-Enrollment in Galena's (GALE) Phase III PRESENT Should Strengthen Validity of Results - Roth Capital
-
Notable Analyst Rating Changes 4/14: (PAY) (AEZS) (MDR) Upgraded; (AMTD) (SANM) (WWWW) Downgraded
-
Roth Capital Starts uniQure BV (QURE) at Buy
-
Roth 'Encouraged' by Cytori Therapeutics' (CYTX) Scleradec-I Study; Sees Mid-2015 Start for STAR Study
-
Roth Capital Starts Calgon Carbon Corp. (CCC) at Buy
-
Galena Biopharma Announces Closing of Over-Allotment Option, Increasing Total Gross Proceeds to $43.7 Million
-
Roth Capital Downgrades ANI Pharmaceuticals (ANIP) to Neutral
-
BioBlast Pharma's (ORPN) Cabaletta Fast Track Designation Viewed as Incremental Positive by Roth Capital; 'Buy' Rating Affirmed
-
Conatus Announces Completion of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Conatus Announces Completion of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Notable 52-Week Highs and Lows 4/8: (ADXS) (LULU) (DG) High; (SPPI) (CEQP) Low
-
Door Now Open for Sandoz's Generic Version of Spectrum Pharma's (SPPI) Fusilev; Roth Affirms at 'Neutral'

